Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial

Background: Although dual blockade HER2-based neoadjuvant chemotherapy is associated with excellent outcomes for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, pertuzumab is not available to all patients due to cost. The optimal neoadjuvant chemotherapy for HER2-positive bre...

Full description

Bibliographic Details
Main Authors: Hong-Fei Gao, Zhiyong Wu, Ying Lin, Xiang-Yang Song, Yin Cao, Qian-Jun Chen, Gangling Zhang, Peifen Fu, Zhenzhen Liu, Liu-Lu Zhang, Ci-Qiu Yang, Mei Yang, Teng Zhu, Fei Ji, Jie-Qing Li, Min-Yi Cheng, Kun Wang
Format: Article
Language:English
Published: SAGE Publishing 2021-04-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359211009003
_version_ 1818640947302367232
author Hong-Fei Gao
Zhiyong Wu
Ying Lin
Xiang-Yang Song
Yin Cao
Qian-Jun Chen
Gangling Zhang
Peifen Fu
Zhenzhen Liu
Liu-Lu Zhang
Ci-Qiu Yang
Mei Yang
Teng Zhu
Fei Ji
Jie-Qing Li
Min-Yi Cheng
Kun Wang
author_facet Hong-Fei Gao
Zhiyong Wu
Ying Lin
Xiang-Yang Song
Yin Cao
Qian-Jun Chen
Gangling Zhang
Peifen Fu
Zhenzhen Liu
Liu-Lu Zhang
Ci-Qiu Yang
Mei Yang
Teng Zhu
Fei Ji
Jie-Qing Li
Min-Yi Cheng
Kun Wang
author_sort Hong-Fei Gao
collection DOAJ
description Background: Although dual blockade HER2-based neoadjuvant chemotherapy is associated with excellent outcomes for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, pertuzumab is not available to all patients due to cost. The optimal neoadjuvant chemotherapy for HER2-positive breast cancer in the presence of a single HER2 blockade is unknown. This study aimed to compare the efficacy and safety of epirubicin/cyclophosphamide followed by docetaxel/trastuzumab (EC-TH) with docetaxel/carboplatin/trastuzumab (TCH) neoadjuvant setting for HER2-positive breast cancer under the single HER2 blockade. Methods: Patients with stage II-IIIC HER2-positive breast cancer were randomly assigned to either eight cycles of EC-TH every 3 weeks during all chemotherapy cycles, or six cycles of TCH every 3 weeks. The primary endpoint was pathological complete response (pCR) (defined as the absence of invasive tumor cells in breast and axilla, ypT0/is ypN0). Results: From May 2017 to November 2019, 140 patients were randomly assigned, and 135 patients were ultimately found evaluable for the primary endpoint. The pCR was recorded in 25 of 67 patients [37.3%; 95% confidence interval (CI), 25.8–50.0] in the EC-TH group and in 38 of 68 patients (55.9%, 95% CI, 43.3–67.9) in the TCH group ( p  = 0.032). The most common adverse events (AEs) were neutropenia in 24 of 67 (35.8%) patients in the EC-TH group versus 27 of 68 (39.7%) in the TCH group ( p  = 0.642), anemia in 33 of 67 (49.3%) patients in the EC-TH group versus 34 of 68 (50.0%) in the TCH group ( p  = 0.931), and thrombocytopenia in five of 67 (7.5%) patients in the EC-TH group versus 17 of 68 (25.0%) in the TCH group ( p  = 0.006). Conclusion: For patients receiving the single HER2 blockade trastuzumab for HER2-positive breast cancer, TCH regimen might be a preferred neoadjuvant therapy. Trial registration: This trial was registered with ClinicalTrials.gov identifier: NCT03140553) on 2 May 2017.
first_indexed 2024-12-16T23:19:22Z
format Article
id doaj.art-d036c3fd9787471f81ac0cd6a23b620a
institution Directory Open Access Journal
issn 1758-8359
language English
last_indexed 2024-12-16T23:19:22Z
publishDate 2021-04-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Medical Oncology
spelling doaj.art-d036c3fd9787471f81ac0cd6a23b620a2022-12-21T22:12:12ZengSAGE PublishingTherapeutic Advances in Medical Oncology1758-83592021-04-011310.1177/17588359211009003Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trialHong-Fei GaoZhiyong WuYing LinXiang-Yang SongYin CaoQian-Jun ChenGangling ZhangPeifen FuZhenzhen LiuLiu-Lu ZhangCi-Qiu YangMei YangTeng ZhuFei JiJie-Qing LiMin-Yi ChengKun WangBackground: Although dual blockade HER2-based neoadjuvant chemotherapy is associated with excellent outcomes for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, pertuzumab is not available to all patients due to cost. The optimal neoadjuvant chemotherapy for HER2-positive breast cancer in the presence of a single HER2 blockade is unknown. This study aimed to compare the efficacy and safety of epirubicin/cyclophosphamide followed by docetaxel/trastuzumab (EC-TH) with docetaxel/carboplatin/trastuzumab (TCH) neoadjuvant setting for HER2-positive breast cancer under the single HER2 blockade. Methods: Patients with stage II-IIIC HER2-positive breast cancer were randomly assigned to either eight cycles of EC-TH every 3 weeks during all chemotherapy cycles, or six cycles of TCH every 3 weeks. The primary endpoint was pathological complete response (pCR) (defined as the absence of invasive tumor cells in breast and axilla, ypT0/is ypN0). Results: From May 2017 to November 2019, 140 patients were randomly assigned, and 135 patients were ultimately found evaluable for the primary endpoint. The pCR was recorded in 25 of 67 patients [37.3%; 95% confidence interval (CI), 25.8–50.0] in the EC-TH group and in 38 of 68 patients (55.9%, 95% CI, 43.3–67.9) in the TCH group ( p  = 0.032). The most common adverse events (AEs) were neutropenia in 24 of 67 (35.8%) patients in the EC-TH group versus 27 of 68 (39.7%) in the TCH group ( p  = 0.642), anemia in 33 of 67 (49.3%) patients in the EC-TH group versus 34 of 68 (50.0%) in the TCH group ( p  = 0.931), and thrombocytopenia in five of 67 (7.5%) patients in the EC-TH group versus 17 of 68 (25.0%) in the TCH group ( p  = 0.006). Conclusion: For patients receiving the single HER2 blockade trastuzumab for HER2-positive breast cancer, TCH regimen might be a preferred neoadjuvant therapy. Trial registration: This trial was registered with ClinicalTrials.gov identifier: NCT03140553) on 2 May 2017.https://doi.org/10.1177/17588359211009003
spellingShingle Hong-Fei Gao
Zhiyong Wu
Ying Lin
Xiang-Yang Song
Yin Cao
Qian-Jun Chen
Gangling Zhang
Peifen Fu
Zhenzhen Liu
Liu-Lu Zhang
Ci-Qiu Yang
Mei Yang
Teng Zhu
Fei Ji
Jie-Qing Li
Min-Yi Cheng
Kun Wang
Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial
Therapeutic Advances in Medical Oncology
title Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial
title_full Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial
title_fullStr Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial
title_full_unstemmed Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial
title_short Anthracycline-containing carboplatin-containing neoadjuvant chemotherapy in combination with trastuzumab for HER2-positive breast cancer: the neoCARH phase II randomized clinical trial
title_sort anthracycline containing carboplatin containing neoadjuvant chemotherapy in combination with trastuzumab for her2 positive breast cancer the neocarh phase ii randomized clinical trial
url https://doi.org/10.1177/17588359211009003
work_keys_str_mv AT hongfeigao anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT zhiyongwu anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT yinglin anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT xiangyangsong anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT yincao anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT qianjunchen anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT ganglingzhang anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT peifenfu anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT zhenzhenliu anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT liuluzhang anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT ciqiuyang anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT meiyang anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT tengzhu anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT feiji anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT jieqingli anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT minyicheng anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial
AT kunwang anthracyclinecontainingcarboplatincontainingneoadjuvantchemotherapyincombinationwithtrastuzumabforher2positivebreastcancertheneocarhphaseiirandomizedclinicaltrial